X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
INB-400 is an autologous gamma-delta T cell therapy product candidate, currently undergoing assessment in mid-stage clinical trials for treating glioblastoma.
Lead Product(s): INB-400,Temozolomide
Therapeutic Area: Oncology Product Name: INB-400
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
IN8bio intends to use the net proceeds to fund the clinical development of its product candidates, including INB-100, an allogeneic product candidate initially developed for the treatment of patients with acute leukemia undergoing hematopoietic bone marrow transplantation.
Lead Product(s): INB-100
Therapeutic Area: Oncology Product Name: INB-100
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.
Deal Size: $46.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 11, 2023
Details:
INB-200 is the first genetically engineered gamma-delta T cell therapy to be administered to patients with solid tumors. It is under phase 1/2 clinical development for the treatment of glioblastoma.
Lead Product(s): Autologous Genetically Modified Gamma-delta T Cells,Temozolomide
Therapeutic Area: Oncology Product Name: INB-200
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
INB-100, IN8bio’s DeltEx Allo, is an allogeneic product candidate, initially developed for the treatment of patients with hematologic malignancies undergoing hematopoietic bone marrow transplantation (HSCT).
Lead Product(s): INB-100
Therapeutic Area: Oncology Product Name: INB-100
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
INB-400 is an autologous, genetically engineered gamma-delta T cell therapy that was recently cleared by the FDA for a Phase 2 trial targeting newly diagnosed glioblastoma multiforme (GBM).
Lead Product(s): INB-400,Temozolomide
Therapeutic Area: Oncology Product Name: INB-400
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation.
Lead Product(s): INB-100
Therapeutic Area: Oncology Product Name: INB-100
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
INB-400 is IN8bio’s DeltEx chemotherapy resistant autologous and allogeneic DRI technology. Allogeneic INB-400 will expand the application of DRI gamma-delta T cells into other solid tumor types through the development of allogeneic or “off-the-shelf” DeltEx DRI technology.
Lead Product(s): INB-400
Therapeutic Area: Oncology Product Name: INB-400
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
The collaboration provides IN8bio exclusive access to a state-of-the-art GMP manufacturing facility and is structured to support the Company’s anticipated INB-400 Phase 2 clinical program in glioblastoma.
Lead Product(s): INB-400
Therapeutic Area: Oncology Product Name: INB-400
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: University of Louisville
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 15, 2022
Details:
INB-200, our DeltEx DRI, is a genetically modified autologous gamma-delta T cell product candidate, to be administered to patients in indication is newly diagnosed Glioblastoma.
Lead Product(s): INB-200
Therapeutic Area: Oncology Product Name: INB-200
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: University of Alabama at Birmingham
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
INB-300, (DeltEx DRI CAR-T), is a preclinical product candidate combining expertise in gamma-delta T cells, our DRI technology and a novel CAR-directed against the Cholotoxin peptide.
Lead Product(s): DeltEx DRI Chlorotoxin CAR-T
Therapeutic Area: Oncology Product Name: INB-300
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
